Ukljucite javascript
Register Log in
HOME ARCHIVE ABOUT US EDITORIAL BOARD REVIEWERS FOR AUTHORS CONTACT

Archive > Year 2007, Number 2

The Role Of Exercise In Preventing And Treating Hiv Infection And Cancer


Authors

Dopsaj Violeta, Faculty of Pharmacy, University of Belgrade
Veljković Milena, Institute of Nuclear Sciences Vinča
Veljković Nevena, Institute of Nuclear Sciences Vinča

Abstract

It is shown in this article that physical exercise can significantly contribute to prevention and suppression of disease development in HIV infected individuals. The findings presented in this review show that physical exercise induces production of anti-vasoactive intestinal peptide (anti-VIP) antibodies in the sera of both HIV infected and non-infected individuals by increasing the level of VIP protein. Negative correlation observed between progression of HIV disease and level of anti-VIP antibodies titer in HIV infected patients reflects decrease in amount of HIV particles present in the circulation, which occur as a consequence of the anti-VIP antibodies’ high affinity for HIV gp120 antigen. Taking into account deficiencies of currant medical therapies for AIDS and lack of prospective vaccine, aerobic physical exercise can be considered as highly promising and widely accessible non-toxic therapy for AIDS.

Keywords

HIV, vasoactive intestinal peptide (VIP), cancer, physical exercise

Download full article

References

  1. Bradac, J. A., & Mathieson, B. J. (1991). An epitope map of immunity to HIVHIV-1: a roadmap for vaccine development. Div. of AIDS, NIAID, NIH.
  2. De la Fuente, M., Delgado, M., & Gomeriz, R.P. (1996). VIP modulation of immune cell functions. Advances in Neuroimmunology. 6: 75-91.
  3. Galbo, H., Hilsted, J., Fahrenkrug, .J, & Schaffalitzky De Muckadell, O.B. (1979). Fasting and prolonged exercise increase vasoactive intestinal polypeptide (VIP) in plasma. Acta. Physiol. Scand., 5: 374-377.
  4. Ganea, D, & Sun, L. (1993). Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes. J. Neuroimmunol., 47: 147-158.
  5. Hilsted, J., Galbo, H., Sonne, B., Schwartz, T., Fahrenkrug, J., de Muckadell, OB., Lauritsen, K. B., & Tronier, B. (1980). Gastroenteropancreatic hormonal changes during exercise. Am. J. Physiol., 239: G136-140.
  6. Hvidsten, D., Jenssen, T. G., Bolle, R., & Burhol, P. G. (1986). Plasma gastrointestinal regulatory peptides in exercise-induced asthma. Eur. J. Respir. Dis., 68: 326-331.
  7. Johnson, J., Anders, G., Blanton, H., Hawkes, C., Bush, B., McAllister, C., & Matthews, J., (1990). Exercise dysfunction in patients seropositive for the human immunodeficiency virus-1. Am. Rev. Respir. Dis., 141: 618-622.
  8. MacArthur, R. D., Levine, S. D., & Berk, T. J. (1993). Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med. Sci. Sports Exerc., 25: 684-688
  9. MacLaren, D. P., Raine, N. M., O'Connor, A. M., & Buchanan, K. D. (1995). Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested. Clin. Sci. (Colch)., 89: 137-143.
  10. Metlaš, R., Trajkovic, D., Srdic, T., Veljković, V., & Colombatti, A. (1999). Human immunodeficency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. AIDS Res. Hum. Retrovir., 15: 671-677.
  11. Metlaš, R., Trajković, D., Srdic, T., Veljković, V. & Colombatti, A. (1999). Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. J. Acquir. Immune. Defic. Synd., 21: 266-270.
  12. Metlaš, R., & Veljković, V. (1995). Does HIV-1 gp120 manipulate human immune network. Vaccine. 13: 355-359.
  13. Neurath, A. R., Strick, N., Taylor, P., Rubinstein, P., & Stevens, C. E. (1990). Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistence to disease development. AIDS Res. Human Retrovir., 6: 1183-1192.
  14. Nio, D. A., Moylan, R. N., & Roche, J. K. (1993). Modulation of T lymphocyte function by neuropeptide. Evidence for their role as local immunoregulatory elements. J. Immunol., 150: 5281-5288.
  15. Oktedalen O., Opstad P. K., Fahrenkrug J., & Fonnum F. (1983). Plasma concentration of vasoactive intestinal polypeptide during prolonged physical exercise, calorie supply deficiency, and sleep deprivation. Scand. J. Gastroenterol., 18: 1057-1062.
  16. Oktedalen O., Opstad P. K., de Muckadell O. B. (1983). The plasma concentration of secretin and vasoactive intestinal polypeptide (VIP) after long-term, strenuous exercise. Eur. J. Physiol. Occup. Physiol., 52: 5-8.
  17. Oktedalen, O., Opstad, P. K., Schaffalitzky de Muckadell, O. B., Fausa, O., & Flaten, O. (1983). Basal hyperchlorhydria and its relation to the plasma concentrations of secretin, vasoactive intestinal polypeptide (VIP) and gastrin during prolonged strain. Regul. Pept., 5: 235-244.
  18. Opstad, P. K. (1987). The plasma vasoactive intestinal peptide (VIP) response to exercise is increased after prolonged strain, sleep and energy deficiency and extinguished by glucose infusion. Peptides. 8: 175-178.
  19. Paul, S., Heinz-Erian, P., & Said, S. I. (1985). Autoantibody to vasoactive intestinal peptide in human circulation. Biochem. Biophys. Res. Commun., 130: 479-485.
  20. Paul, S., & Said, S. I. (1988). Human autoantibody to vasoactive intestinal peptide: increased incidence in muscular exercise. Life Sci., 43: 1079-1084.
  21. Paul, S. (1987). Elevated levels of atrial natriuretic peptide and vasoactive intestinal peptide in exercising man. Clin. Res., 35: 112A.
  22. Perna, F. M, LaPerriere, A., Klimas, N. G., Ironson, G., Perry, A., Pavone, J., Goldstein, A., Majors, P., Makemson, D., Talutto, C., Schneiderman, N., Fletcher, MA., Meijer, OG., Koppes, L. (1999). Cardiopulmonary and CD4 changes in response to exercise training in early symptomatic HIV infection. Med. Sci. Sports Med., 31: 973-979.
  23. Pothoff, G., Wasserman, K., & Ostmann, H. (1994). Impairment of exercise capacity in various groups of HIV-infected patients. Respiration. 61: 80-85.
  24. Rakowicz-Szulczynska, E. M., Markowski, M., Mackiewicz, A., Karczewska, A., Snyder, W., McIntosh, D. G., Kapcinska, M., & Smith, M. L. (1997). New protein and PCR marker RAK for diagnosis, prognosis and surgery guidance for breast cancer. Cancer Lett., 112: 93-101.
  25. Rakowicz-Szulczynska, E. M., Jackson, B., & Snyder, W. (1998). Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. Cancer Lett., 124: 213-223.
  26. Rakowicz-Szulczynska, E. M., Jackson, B., Szulczynska, A. M., & Smith M. (1998). Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer. Clin. Diagnost. Lab. Immunol., 5: 645-653.
  27. Rakowicz-Szulczynska, E. M., McIntosh, D. G., & Smith, M. (1999). Giant syncytia and virus-like particles in ovarian carcinoma cell isolated from ascites fluid. Clin. Diagnost. Lab. Immunol., 6: 115-126.
  28. Rakowicz-Szulczynska, E. M. (2000). Relevance of the voral RAK alpha gene in diagnosis of malignant versus nonmalignant tumors of the ovary and uterus. Clin. Diagn. Lab. Immunol., 7: 360-365.
  29. Rakowicz-Szulczynska, E. M., McIntosh, D. G., Perryl, M. J., & Smith, M. J. (1995). Mechanisms of cancer growth promotion by HIV-1 neutralizing antibodies. Cancer J., 8: 143-149.
  30. Rakowicz-Szulczynska, E. M. (1996). Detection and treatment of breast and gynecological cancer. US Pat. No. 5,939,277.
  31. Rigsby, L. W., Dishman, R. K., Jackson, A. W., Maclean, G. S., & Raven, PB. (1992). Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med. Sci. Sports Exerc., 24: 6-12.
  32. Stringer, W. W. (1999). HIV and Aerobic Exercise: Current Recommendations. Sports Medicine. 28: 389-395.
  33. Stringer, W. W., Berezovskaya, M., O'Brien, WA., Beck, CK. Casaburi, R. (1998). The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med. Sci. Sports Exerc., 30: 11-16.
  34. Sun, L., & Ganea, D. (1993). Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J. Neuroimmunol., 48: 59-69.
  35. Teresi, S., Boudard, F., & Bastide, M. (1996). Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8 T cell proliferation. Immunol. Lett., 50: 105-113.
  36. Terry, L., Sprinz, E., & Ribeiro, J. P. (1999). Moderate and high intensity exercise training in HIV-1 seropositive individuals: a randomized trail. Int. J. Sports Med., 20(2): 142-146.
  37. Veljkovic, V., & Slavic I. (1972). General model pseudopotential. Phys Rev Lett., 29:105.
  38. Veljkovic, V. (1980). Theoretical Approach to Preselection of Carcinogens and Chemical Carcinogenesis. New York: Gorgon & Breach Sci Pub.
  39. Veljković, V., Johnson E., & Metlaš R. (1995). Analogy of HIV-1 to oncogenic viruses: possible implications for the pathogenesis of AIDS. Cancer J., 8: 308-316.
  40. Veljković, V., & Metlaš R. (1988). Identification of nanopeptide from HTLV3, LAV and ARV-2 envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem. Biophys., 10: 91-106.
  41. Veljković, V., Metlaš, R., Raspopović, J., & Pongor, S. (1992). Spectral and sequence similarity between VIP and the second conserved region of HIV envelope glycoprotein gp120: possible consequences on prevention and therapy of AIDS., Biochem. Biophys. Res. Commun., 189: 705-710.
  42. Veljković V., Metlaš, R., Vojvodić, D., Čavor, Lj., Pejinović, N., Dujić, A., Zakhariev, S., Guarnaccia, C., & Pongor, S. (1993). Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120., Biochem. Biophys. Res. Commun., 196: 1019-1024.
  43. Veljković, V., & Metlaš, R. (1992). HIV and idiotypic regulation: another view. Immunol. Today., 15: 38
  44. Veljković, V., Metlaš, R, Jevtovic, D., & Stringer W. W. (2001). The role of passive immunization in HIV-positive patients : a case report. Chest. 120(2): 662-666.
  45. Wang, H. F., Xin, Z., Tang, H., & Ganea, D. (1996). Vasoactive intestinal peptide inhibits IL-4 production in murine T cell by a post-trascriptional mechanism. J. Immunol., 156: 3243-3253.
  46. Wiik, P., Opstad, P. K., Knardahl, S., & Boyum, A. (1988). Receptor for vasoactive intestinal peptide (VIP) on human mononuclear leucocytes are upregulated during prolonged strain and energy deficiency. Peptides. 9: 181-186.
  47. Woie, L., Kaada, B., & Opstad, P. K. (1986). Increase in plasma vasoactive intestinal polypeptide (VIP) in muscular exercise in humans. Gen. Pharmacol., 17: 321-326.
  48. Xin, Z., Tang, H., & Ganea, D. (1994). Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J. Neuroimmunol., 54: 59-68.
  49. Yiangou, Y., Serrano, R., Bloom, S. R., Pena, J., & Festenstein, H. (1990). Effects of prepro-vasoactive intestinal peptide-derived peptides on the murine immune response. J. Neuroimmunol., 29: 65-72.

©2012 Sports Academy Belgrade. All rights reserved. Powered by Magma
Publication of this journal is financially supported by the Ministry of Science, Technology and Development Republic of Serbia.